High-purity quinoline derivative and method for manufacturing same

• US 10,407,393 B2
• Filed: 12/21/2018
• Issued: 09/10/2019
• Est. Priority Date: 08/28/2014
• Status: Active Grant

• Current Assignee: Eisai R & D Management Company Limited (Eisai Medical Research Incorporated)
• Original Assignee: Eisai R & D Management Company Limited (Eisai Medical Research Incorporated)
• Inventors: Nakamura, Taiju, Abe, Taichi, Miyashita, Yusuke, Kuroda, Hirofumi, Ayata, Yusuke, Akao, Atsushi
• Primary Examiner(s): Seaman, D Margaret M
• Application Number:
  US16/229,805
• Publication Number:
  US 20190185432A1
• Time in Patent Office: 263 Days
• CPC Class Codes: A61K 31/47 Quinolines; Isoquinolines
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07D 215/48 Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Abstract

Provided is a compound represented by formula (IV) or a salt thereof, wherein the content of the compound represented by formula (I) is 350 ppm by mass or less.

Claims

1. A methanesulfonate salt of a compound represented by formula (IV), wherein the content of a compound represented by formula (I) is 183 ppm by mass or less

2. The methanesulfonate salt of a compound represented by formula (IV) according to claim 1, wherein the content of the methanesulfonate salt of a compound represented by formula (IV) is 98.0% by mass or more.

3. The methanesulfonate salt of a compound represented by formula (IV) according to claim 1, wherein the content of the compound represented by formula (I) is determined by HPLC.